MCID: SPN040
MIFTS: 37

Spinal Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Spinal Cancer

MalaCards integrated aliases for Spinal Cancer:

Name: Spinal Cancer 12 14
Spinal Cord Neoplasms 41 69
Spinal Cord Neoplasm 12 72
Spinal Neoplasms 41 69
Malignant Tumor of the Spinal Cord 12
Tumor of the Spinal Cord 12
Intraspinal Neoplasm 69
Spinal Cord--Cancer 69
Spinal Cord Cancer 12
Spinal Cord Tumors 50
Tumors Spinal Cord 51
Intraspinal Tumor 12
Spinal Cord Tumor 28
Spinal Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5612
ICD10 32 C72.0
ICD9CM 34 192.2
NCIt 46 C3381 C3572

Summaries for Spinal Cancer

NINDS : 50 Tumors of the brain and spinal cord are abnormal growths of tissue found inside the skull or the bony spinal column.  The brain and spinal cord are the primary components of the central nervous system (CNS). Benign tumors are noncancerous, and malignant tumors are cancerous. The CNS is housed within rigid, bony quarters (i.e., the skull and spinal column), so any abnormal growth, whether benign or malignant, can place pressure on sensitive tissues and impair function. Tumors that originate in the brain or spinal cord are called primary tumors. Most primary tumors are caused by out-of-control growth among cells that surround and support neuron, specific genetic disease (such as neurofibromatosis type 1 and tuberous sclerosis), or from exposure to radiation or cancer-causing chemicals. Metastatic, or secondary, tumors in the CNS are caused by cancer cells that break away from a primary tumor located in another region of the body. Tumors can place pressure on sensitive tissues and impair function..Symptoms of brain tumors include headaches, seizures, nausea and vomiting, poor vision or hearing, changes in behavior, unclear thinking, and unsteadiness.  Spinal cord tumor symptoms include pain, numbness, and paralysis. Diagnosis is made after a neurological examination, special imaging techniques (computed tomography, and magnetic resonance imaging, positron emission tomography), laboratory tests, and a biopsy (in which a sample of tissue is taken from a suspected tumor and examined).

MalaCards based summary : Spinal Cancer, also known as spinal cord neoplasms, is related to spinal meningioma and spinal cord glioma. An important gene associated with Spinal Cancer is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Pathways Affected in Adenoid Cystic Carcinoma and Regulation of Androgen receptor activity. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include the spinal cord, spinal cord and testes, and related phenotype is Increased proliferation.

Disease Ontology : 12 A central nervous system cancer that is located in the spinal cord. It is mostly formed from metastases from primary cancers elsewhere (commonly breast, prostate, and lung cancer).

Wikipedia : 72 Spinal tumors are neoplasms located in the spinal cord. Extradural tumors are more common than... more...

Related Diseases for Spinal Cancer

Diseases related to Spinal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 spinal meningioma 30.7 CYP4F22 FAT2 NF2 SMARCE1
2 spinal cord glioma 30.4 HOXB13 NRXN2 TP53
3 ganglioglioma 29.4 GFAP TP53
4 childhood spinal cord tumor 11.1
5 spinal cord lymphoma 10.7
6 intraventricular meningioma 10.4 GFAP NF2
7 cornea cancer 10.4 GFAP NF2
8 rhabdoid meningioma 10.4 GFAP NF2
9 benign ependymoma 10.4 GFAP NF2
10 plexiform schwannoma 10.4 GFAP NF2
11 atypical neurofibroma 10.4 GFAP NF2
12 anaplastic ependymoma 10.4 GFAP NF2
13 tanycytic ependymoma 10.4 GFAP NF2
14 cerebellopontine angle tumor 10.3 GFAP NF2
15 pancreatic gastrinoma 10.3 GFAP NRXN2
16 clear cell meningioma 10.3 GFAP SMARCE1
17 ependymoma 10.3 GFAP NF2
18 meningothelial meningioma 10.3 NF2 SMARCE1
19 neurilemmoma 10.2 GFAP NF2
20 neurilemmomatosis 10.2 NF2 SMARCE1
21 myxopapillary ependymoma 10.2 GFAP HOXB13
22 neuroma 10.2 GFAP NF2
23 hemangioblastoma 10.1
24 frontal convexity meningioma 10.1 GFAP TP53
25 gliofibroma 10.1 GFAP TP53
26 protoplasmic astrocytoma 10.1 GFAP TP53
27 cellular ependymoma 10.1 GFAP TP53
28 central nervous system primitive neuroectodermal neoplasm 10.1 GFAP TP53
29 cerebral neuroblastoma 10.1 GFAP TP53
30 mixed glioma 10.1 GFAP TP53
31 ependymoblastoma 10.0 GFAP TP53
32 cerebral ventricle cancer 10.0 GFAP TP53
33 cerebrum cancer 10.0 GFAP TP53
34 hemangiopericytoma, malignant 10.0
35 olfactory groove meningioma 10.0 NF2 TP53
36 supratentorial cancer 10.0 GFAP TP53
37 fibrillary astrocytoma 10.0 GFAP TP53
38 pleomorphic xanthoastrocytoma 10.0 GFAP TP53
39 gliomatosis cerebri 10.0 GFAP TP53
40 papilloma of choroid plexus 10.0 GFAP TP53
41 spinal cord astrocytoma 10.0 GFAP TP53
42 anterior cranial fossa meningioma 10.0 NF2 TP53
43 choroid plexus cancer 10.0 GFAP TP53
44 necrotizing sialometaplasia 10.0 GFAP TP53
45 cystic teratoma 10.0 GFAP TP53
46 small cell sarcoma 10.0 NF2 TP53
47 cerebellar liponeurocytoma 10.0 GFAP TP53
48 medullomyoblastoma 10.0 GFAP TP53
49 adult medulloblastoma 10.0 GFAP TP53
50 optic nerve neoplasm 10.0 NF2 TP53

Graphical network of the top 20 diseases related to Spinal Cancer:



Diseases related to Spinal Cancer

Symptoms & Phenotypes for Spinal Cancer

GenomeRNAi Phenotypes related to Spinal Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

Drugs & Therapeutics for Spinal Cancer

Drugs for Spinal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
2
Etoposide Approved Phase 3,Phase 1,Phase 2,Not Applicable 33419-42-0 36462
3
Cisplatin Approved Phase 3,Phase 1 15663-27-1 2767 441203 84093
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
6
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
7
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 4342-03-4 5351166
8
Minocycline Approved, Investigational Phase 2, Phase 3 10118-90-8 5281021
9
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 85622-93-1 5394
10
Lomustine Approved, Investigational Phase 3,Phase 2 13010-47-4 3950
11
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
12
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
14
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
15
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
16
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18 Isophosphamide mustard Phase 3,Phase 1,Phase 2 0
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 glucocorticoids Phase 3,Phase 1
21 Folic Acid Antagonists Phase 3
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
23 Nucleic Acid Synthesis Inhibitors Phase 3
24 Hormone Antagonists Phase 3,Phase 2,Phase 1
25 Dermatologic Agents Phase 3,Phase 1,Phase 2
26 Vitamin B Complex Phase 3
27 Hormones Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
29 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
30 Anti-Infective Agents Phase 2, Phase 3,Phase 1
31 Etoposide phosphate Phase 3,Phase 1,Phase 2,Not Applicable
32 Immunosuppressive Agents Phase 3,Phase 1
33 Antimetabolites Phase 3
34 Anti-Inflammatory Agents Phase 3,Phase 1
35 Antimetabolites, Antineoplastic Phase 3
36 Antimitotic Agents Phase 3,Phase 1,Phase 2,Not Applicable
37 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
39 Antirheumatic Agents Phase 3,Phase 1
40 Calcium, Dietary Phase 3
41 Dexamethasone acetate Phase 3,Phase 1 1177-87-3
42 Mitogens Phase 2, Phase 3
43 Adrenocorticotropic Hormone Phase 3
44 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
45 Corticotropin-Releasing Hormone Phase 3
46 Histone Deacetylase Inhibitors Phase 2, Phase 3,Phase 1
47 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
48 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
49 Peripheral Nervous System Agents Phase 3,Phase 1
50 Antibodies, Monoclonal Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 70)

# Name Status NCT ID Phase Drugs
1 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
2 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
4 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
5 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
6 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
7 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
8 Cyberknife Precision Radiation Delivery System for Tumors of the Spine Completed NCT00185666 Phase 1, Phase 2
9 A Phase I/II Study of the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
10 Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma Completed NCT00124657 Phase 1, Phase 2 Erlotinib hydrochloride
11 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma Completed NCT00028795 Phase 2 temozolomide
12 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
13 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
14 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
15 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
16 Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
17 Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS) Active, not recruiting NCT00508443 Phase 1, Phase 2
18 Evaluation of Single Session Stereotactic Body Radiotherapy Active, not recruiting NCT00492817 Phase 1, Phase 2
19 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas Active, not recruiting NCT00100802 Phase 2 lomustine;temozolomide
20 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
21 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
22 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
23 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
24 Photodynamic Therapy for the Treatment of Vertebral Metastases Completed NCT02464761 Phase 1 Visudyne
25 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
26 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
27 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
28 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
29 Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Completed NCT00107458 Phase 1 valproic acid
30 SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
31 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
32 Intra-arterial Chemotherapy for Spinal Metastases Recruiting NCT01637766 Phase 1 Melphalan (intra-arterial infusion)
33 Indocyanine Green for Central Nervous System Tumors, Tumor Glow Enrolling by invitation NCT03262636 Phase 1 Indocyanine Green
34 Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer Terminated NCT01407341 Phase 1
35 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
36 MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer Terminated NCT00572182 Phase 1 MK-0752
37 Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment Withdrawn NCT00458744 Phase 1 talotrexin
38 Impact of Balanced Slat Colloid HES 130/0.42 on Coagulation Profiles in Patients Undergoing Spinal Cord Tumor Surgery Unknown status NCT01921595 Not Applicable
39 Establishment of a Brain and Spinal Tumor Tissue Bank Unknown status NCT00686387
40 The Development of a Vertebra Localizing Aid Medical Device Unknown status NCT02603874 Not Applicable
41 Spinal Motor Evoked Potentials in Brain Surgery Unknown status NCT02402075
42 Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery Unknown status NCT02527304 Not Applicable
43 Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer Unknown status NCT00349024 Not Applicable polyvinylpyrrolidone-sodium hyaluronate gel
44 Direct Injection of Alcohol for the Treatment of Spinal Tumors Completed NCT00001417
45 Alternative Treatment of Giant Spinal Schwannomas Completed NCT02494622
46 Development of the MDASI-Spine Tumor Module Completed NCT00430872
47 Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord Completed NCT00631670 Not Applicable
48 A Clinical Study of a Spine Fusion System in Vertebral Body Fusion Surgery Completed NCT02252185 Not Applicable
49 Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma Completed NCT00077207 Not Applicable carboplatin;temozolomide;vincristine sulfate
50 Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain Completed NCT00452868 Early Phase 1 Donepezil

Search NIH Clinical Center for Spinal Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: spinal cord neoplasms

Genetic Tests for Spinal Cancer

Genetic tests related to Spinal Cancer:

# Genetic test Affiliating Genes
1 Spinal Cord Tumor 28

Anatomical Context for Spinal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Spinal Cancer:

18
The Spinal Cord

MalaCards organs/tissues related to Spinal Cancer:

38
Spinal Cord, Testes, Prostate, Lung, Brain

Publications for Spinal Cancer

Articles related to Spinal Cancer:

# Title Authors Year
1
Surgical vertebral body cementoplasty as spinal cancer metastasis management. ( 25548834 )
2014
2
A study investigating the validity of modified Tokuhashi score to decide surgical intervention in patients with metastatic spinal cancer. ( 22899107 )
2013
3
An in vivo mouse model of intraosseous spinal cancer causing evolving paraplegia. ( 23955595 )
2013
4
Survival analysis of 459 adult patients with primary spinal cancer in England and Wales: a population-based study. ( 17210300 )
2007
5
Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. ( 8893440 )
1996

Variations for Spinal Cancer

Cosmic variations for Spinal Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5702591 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 10
2 COSM28746 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 10
3 COSM28747 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 10
4 COSM28749 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 10
5 COSM28748 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 10
6 COSM28750 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 10
7 COSM5702574 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 10
8 COSM5702592 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 10

Expression for Spinal Cancer

Search GEO for disease gene expression data for Spinal Cancer.

Pathways for Spinal Cancer

Pathways related to Spinal Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.78 SMARCE1 TP53
2 10.32 HOXB13 SMARCE1

GO Terms for Spinal Cancer

Cellular components related to Spinal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 8.62 GFAP NF2

Biological processes related to Spinal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to wounding GO:0009611 8.62 GFAP HOXB13

Sources for Spinal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....